Guided lymph node removal after chemo-immunotherapy for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new way to remove lymph nodes during surgery for esophageal cancer after you've already had chemo and immunotherapy. The goal is to see if guiding lymph node removal with a special technique helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with squamous cell carcinoma of the esophagus (the tube that carries food from your throat to your stomach).
- You have already received chemotherapy and immunotherapy before surgery, and your doctors say surgery is still an option.
- Your cancer has not spread to other parts of the body.
- You are between 18 and 75 years old and in generally good health (able to do daily activities without help).
- You do not have a severe autoimmune disease or other major health problems that would make surgery unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy after surgery can help prevent cancer from returning in patients with esophageal squamous cell carcinoma. It is for people who have already received chemotherapy and immunotherapy before surgery and had surgery to remove the cancer, but still had some cancer cells found in the removed tissue.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial compares the current standard treatment (chemotherapy and radiation) with a newer approach that combines chemotherapy and immunotherapy before surgery for esophageal cancer. Participation may help determine if this new combination is more effective for you.
This trial tests a combination of low-dose radiation and immunotherapy for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective after initial treatment.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.